← Leaderboards
David Daniels
Mayo Clinic Rochester
$4,078,623
Attributed
$4,078,623
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2017–24$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,078,623 · 4
By mechanism
R01$1,838,354 · 1
K08$908,385 · 1
R61$899,750 · 1
R33$432,134 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Zhenkun Lou$18,569,951
- Matthew Schuelke$228,427
- Tewodros K. Mamo$130,946
- Tufia C Haddad$809,100
- Richard G Vile$15,977,609
Others in their field
Other Emerging Leaders on “Methionine”
- Harshini Neelakantan · Ridgeline Therapeutics, Llc$3,718,852
- Kayode K Ojo · University Of Washington$3,587,300
- Andrey A Parkhitko · University Of Pittsburgh At Pittsburgh$3,563,772
- Jan Christian Lood · University Of Washington$3,295,299
- Christine Iok In Chio · Columbia University Health Sciences$3,166,178
- Yogesh K Gupta · University Of Texas Hlth Science Center$3,161,127
Research focus
MethionineNovel TherapeuticsMalignant NeoplasmsHistone H3Neoplastic CellMutationLysineChildDiagnosisDiffuse Intrinsic Pontine GliomaMethylation PatternEpigenetic ProcessGene ExpressionChildhood GliomaAffectCellsBrainBrain NeoplasmsCessation Of LifeClinical TrialsCancer CellCell LineGenesPathologic
Grant awards (12)
Development of A High-Throughput Screen for Identification of Targeted Therapies in Brainstem Tumors with the H3K27M Mutation$432,134
R33 · FY2024 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$362,372
R01 · FY2024 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$373,578
R01 · FY2023 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$373,578
R01 · FY2022 · NS · contact PI
Deve inlopment of A High-Throughput Screen for Identification of Targeted Therapies in Brainstem Tumors with the H3K27M Mutation$899,750
R61 · FY2021 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$358,194
R01 · FY2021 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$177,821
K08 · FY2021 · NS · contact PI
Working towards targeted therapy in H3K27M tumors: Aurora Kinase Inhibitors and the role of epigenome programming$370,632
R01 · FY2020 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$183,141
K08 · FY2020 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$183,141
K08 · FY2019 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$182,141
K08 · FY2018 · NS · contact PI
Uncovering Therapeutic Targets in Pediatric High Grade Gliomas with the H3K27M Mutation$182,141
K08 · FY2017 · NS · contact PI